Cargando…
Synergistic Screening of Peptide-Based Biotechnological Drug Candidates for Neurodegenerative Diseases Using Yeast Display and Phage Display
[Image: see text] Peptide therapeutics are robust and promising molecules for treating diverse disease conditions. These molecules can be developed from naturally occurring or mimicking native peptides, through rational design and peptide libraries. We developed a new platform for the rapid screenin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557061/ https://www.ncbi.nlm.nih.gov/pubmed/37638647 http://dx.doi.org/10.1021/acschemneuro.3c00248 |
_version_ | 1785117004323094528 |
---|---|
author | Özçelik, Cemile Elif Beğli, Özge Hınçer, Ahmet Ahan, Recep Erdem Kesici, Mehmet Seçkin Oğuz, Oğuzhan Kasırga, Talip Serkan Özçubukçu, Salih Şeker, Urartu Özgür Şafak |
author_facet | Özçelik, Cemile Elif Beğli, Özge Hınçer, Ahmet Ahan, Recep Erdem Kesici, Mehmet Seçkin Oğuz, Oğuzhan Kasırga, Talip Serkan Özçubukçu, Salih Şeker, Urartu Özgür Şafak |
author_sort | Özçelik, Cemile Elif |
collection | PubMed |
description | [Image: see text] Peptide therapeutics are robust and promising molecules for treating diverse disease conditions. These molecules can be developed from naturally occurring or mimicking native peptides, through rational design and peptide libraries. We developed a new platform for the rapid screening of the peptide therapeutics for disease targets. In the course of the study, we aimed to employ our platform to screen a new generation of peptide therapeutic candidates against aggregation-prone protein targets. Two peptide drug candidates were screened for protein aggregation-prone diseases, namely, Parkinson’s and Alzheimer’s diseases. Currently, there are several therapeutic applications that are only effective in masking or slowing down symptom development. Nonetheless, different approaches are being developed for inhibiting amyloid aggregation in the secondary nucleation phase, which is critical for amyloid fibril formation. Instead of targeting secondary nucleated protein structures, we tried to inhibit the aggregation of monomeric amyloid units as a novel approach for halting the disease condition. To achieve this, we combined yeast surface display and phage display library platforms. We expressed α-synuclein, amyloid β(40), and amyloid β(42) on the yeast surface, and we selected peptides by using phage display library. After iterative biopanning cycles optimized for yeast cells, several peptides were selected for interaction studies. All of the peptides have been used for in vitro characterization methods, which are quartz crystal microbalance-dissipation (QCM-D) measurement, atomic force microscopy (AFM) imaging, dot-blotting, and ThT assay, and some of them have yielded promising results in blocking fibrillization. The rest of the peptides, although, interacted with amyloid units which made them usable as a sensor molecule candidate. Therefore, peptides selected by yeast surface display and phage display library combination are good choice for diverse disease-prone molecule inhibition, particularly those inhibiting fibrillization. Additionally, these selected peptides can be used as drugs and sensors to detect diseases quickly and halt disease progression. |
format | Online Article Text |
id | pubmed-10557061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-105570612023-10-07 Synergistic Screening of Peptide-Based Biotechnological Drug Candidates for Neurodegenerative Diseases Using Yeast Display and Phage Display Özçelik, Cemile Elif Beğli, Özge Hınçer, Ahmet Ahan, Recep Erdem Kesici, Mehmet Seçkin Oğuz, Oğuzhan Kasırga, Talip Serkan Özçubukçu, Salih Şeker, Urartu Özgür Şafak ACS Chem Neurosci [Image: see text] Peptide therapeutics are robust and promising molecules for treating diverse disease conditions. These molecules can be developed from naturally occurring or mimicking native peptides, through rational design and peptide libraries. We developed a new platform for the rapid screening of the peptide therapeutics for disease targets. In the course of the study, we aimed to employ our platform to screen a new generation of peptide therapeutic candidates against aggregation-prone protein targets. Two peptide drug candidates were screened for protein aggregation-prone diseases, namely, Parkinson’s and Alzheimer’s diseases. Currently, there are several therapeutic applications that are only effective in masking or slowing down symptom development. Nonetheless, different approaches are being developed for inhibiting amyloid aggregation in the secondary nucleation phase, which is critical for amyloid fibril formation. Instead of targeting secondary nucleated protein structures, we tried to inhibit the aggregation of monomeric amyloid units as a novel approach for halting the disease condition. To achieve this, we combined yeast surface display and phage display library platforms. We expressed α-synuclein, amyloid β(40), and amyloid β(42) on the yeast surface, and we selected peptides by using phage display library. After iterative biopanning cycles optimized for yeast cells, several peptides were selected for interaction studies. All of the peptides have been used for in vitro characterization methods, which are quartz crystal microbalance-dissipation (QCM-D) measurement, atomic force microscopy (AFM) imaging, dot-blotting, and ThT assay, and some of them have yielded promising results in blocking fibrillization. The rest of the peptides, although, interacted with amyloid units which made them usable as a sensor molecule candidate. Therefore, peptides selected by yeast surface display and phage display library combination are good choice for diverse disease-prone molecule inhibition, particularly those inhibiting fibrillization. Additionally, these selected peptides can be used as drugs and sensors to detect diseases quickly and halt disease progression. American Chemical Society 2023-08-28 /pmc/articles/PMC10557061/ /pubmed/37638647 http://dx.doi.org/10.1021/acschemneuro.3c00248 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Özçelik, Cemile Elif Beğli, Özge Hınçer, Ahmet Ahan, Recep Erdem Kesici, Mehmet Seçkin Oğuz, Oğuzhan Kasırga, Talip Serkan Özçubukçu, Salih Şeker, Urartu Özgür Şafak Synergistic Screening of Peptide-Based Biotechnological Drug Candidates for Neurodegenerative Diseases Using Yeast Display and Phage Display |
title | Synergistic
Screening of Peptide-Based Biotechnological
Drug Candidates for Neurodegenerative Diseases Using Yeast Display
and Phage Display |
title_full | Synergistic
Screening of Peptide-Based Biotechnological
Drug Candidates for Neurodegenerative Diseases Using Yeast Display
and Phage Display |
title_fullStr | Synergistic
Screening of Peptide-Based Biotechnological
Drug Candidates for Neurodegenerative Diseases Using Yeast Display
and Phage Display |
title_full_unstemmed | Synergistic
Screening of Peptide-Based Biotechnological
Drug Candidates for Neurodegenerative Diseases Using Yeast Display
and Phage Display |
title_short | Synergistic
Screening of Peptide-Based Biotechnological
Drug Candidates for Neurodegenerative Diseases Using Yeast Display
and Phage Display |
title_sort | synergistic
screening of peptide-based biotechnological
drug candidates for neurodegenerative diseases using yeast display
and phage display |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557061/ https://www.ncbi.nlm.nih.gov/pubmed/37638647 http://dx.doi.org/10.1021/acschemneuro.3c00248 |
work_keys_str_mv | AT ozcelikcemileelif synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT begliozge synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT hıncerahmet synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT ahanreceperdem synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT kesicimehmetseckin synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT oguzoguzhan synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT kasırgatalipserkan synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT ozcubukcusalih synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay AT sekerurartuozgursafak synergisticscreeningofpeptidebasedbiotechnologicaldrugcandidatesforneurodegenerativediseasesusingyeastdisplayandphagedisplay |